ABHI Statement on NICE’S Final Appraisal Recommendations on the Use of Hybrid Closed-Loop Systems for Managing Type 1 Diabetes
Topic : Position Papers Type : Briefing
ABHI Diabetes[1] welcomes NICE’s decision to recommend hybrid closed-loop (HCL) systems for managing type 1 diabetes.
The recommendations are the culmination of many years of work by NICE, clinicians, NHS England, support groups, industry and others to raise access to HCL technologies and reduce the impact of health inequalities.
Now, hundreds of thousands of people living with type 1 diabetes in England and Wales will be eligible for these proven, next generation technologies to manage their diabetes and improve their quality of life.
ABHI Diabetes is pleased to note that the recommendations are wider than those shared in January’s draft, with advice to offer the tech to all children and young people, a reduction in the clinical criteria and more flexibility in providing the skills people need to use the technology. This was something we and many others called for during the consultation.
Nishan Sunthares, ABHI’s Managing Director, Diagnostics, and Chair, ABHI Diabetes, said "This decision is a significant step forward in improving the lives of people with type 1 diabetes by widening access to proven HealthTech. Hybrid closed-loop systems offer the opportunity to make a real positive difference to those individuals’ health and quality of life. We look forward to working with our partners and stakeholders to support the 5-year phased national rollout and to ensure everyone who needs this technology can benefit from it as quickly as possible.”
[1] ABHI Diabetes is an industry sector group, which operates under the governance of ABHI, and is comprised of member businesses who provide diabetes management technologies including HCL systems.